Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.57 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103228 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1RAB9AGAAPARP10 | |
| SCHEMBL3052606 | 0.94 | LMNA (0.65) | SMN1; SMN2ALDH1A1RAB9AGAAPARP10 | |
| SCHEMBL3052608 | 0.94 | LMNA (0.65) | SMN1; SMN2ALDH1A1RAB9AGAAPARP10 | |
| SCHEMBL18796192 | 0.89 | PTGIR (0.65) | SMN1; SMN2ALDH1A1RAB9AGAAPARP10 | |
| SCHEMBL23864974 | 0.83 | KDM4E (0.56) | SMN1; SMN2ALDH1A1RAB9AGAAPARP10 | |
| SCHEMBL14970879 | 0.81 | PARP10 (0.55) | SMN1; SMN2ALDH1A1RAB9AGAAPARP10 | |
| SCHEMBL9892335 | 0.81 | PRSS1 (0.61) | SMN1; SMN2ALDH1A1RAB9AGAAPARP10 | |
| SCHEMBL21215222 | 0.81 | KDM1A (0.60) | ALDH1A1RAB9AGAALMNAKMT2A | |
| SCHEMBL18615326 | 0.80 | GAA (0.56) | SMN1; SMN2ALDH1A1RAB9AGAAPARP10 | |
| SCHEMBL5423613 | 0.79 | NOS3 (0.68) | SMN1; SMN2ALDH1A1RAB9AGAAPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-20240287054-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4352054-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2023177700-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023073115-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023275744-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022261296-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261296-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| WO-2009010479-A2 | HETEROCYCLIC METHYLENE PIPERIDINE DERIVATIVES AND THEIR USE | EUROSCREEN S.A. (BE) | 2009-01-22 | — | — | WO | disclosed |
| EP-1971602-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007075749-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287054-A1 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | MYC, MYCBP, TNS4 | SMN1; SMN2 2151/4885ALDH1A1 4464/4885RAB9A 2610/4885 |
| US-20090042926-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | SMN1; SMN2 4003/4885ALDH1A1 1145/4885RAB9A 2584/4885 |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | SMN1; SMN2 3115/4885ALDH1A1 4471/4885RAB9A 2370/4885 |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | SMN1; SMN2 3115/4885ALDH1A1 4471/4885RAB9A 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.